Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study.
about
Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules.Raltitrexed plus gemcitabine (TOMGEM) in advanced pancreatic cancer. Results of a Belgian multicentre phase II study.Gemcitabine combined with oxaliplatin (GEMOX) as second-line chemotherapy in patients with advanced ovarian cancer refractory or resistant to platinum and taxane.A dose escalating study of oxaliplatin and high dose weekly leucovorin and 5-Fluorouracil in patients with advanced solid tumors.Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer.Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancerGemcitabine-oxaliplatin combination in heavily pretreated metastatic breast cancer: a pilot study on 43 patients.Gemcitabine combined with oxaliplatin (GEMOX) as salvage treatment in elderly patients with advanced ovarian cancer refractory or resistant to platinum: a single institution experience.Biweekly triple combination chemotherapy with gemcitabine, oxaliplatin, levofolinic acid and 5-fluorouracil (GOLF) is a safe and active treatment for patients with inoperable pancreatic cancer.Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group.Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II studyRationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy).Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analysis of prognostic factors in a salvage setting.Sequential FOLFOX-6 and gemcitabine for locally advanced and/or metastatic pancreatic cancer.Triplet cytotoxic chemotherapy with gemcitabine, 5-fluorouracil and cisplatin for advanced pancreatic cancerEvolution of systemic therapy for advanced pancreatic cancer.Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer.Current and emerging therapies for the treatment of pancreatic cancer.Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II studySystemic therapy for advanced pancreatic cancer.Randomized phase II trials: a long-term investment with promising returnsCell death in response to antimetabolites directed at ribonucleotide reductase and thymidylate synthaseAdjuvant therapy for rectal cancer--the transatlantic view.Advanced pancreatic cancer: is there a role for combination therapy?Review article: chemotherapy for pancreatic cancer.Developments in metastatic pancreatic cancer: is gemcitabine still the standard?Self-assembled nanoscale coordination polymers carrying oxaliplatin and gemcitabine for synergistic combination therapy of pancreatic cancer.Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancerPhase II clinical trials on investigational drugs for the treatment of pancreatic cancersCurrent state of adjuvant therapy in resected pancreatic adenocarcinoma.Efficacy of systemic therapy in advanced pancreatic carcinoma.Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer.Phase II study to evaluate combining gemcitabine with flutamide in advanced pancreatic cancer patientsA novel biweekly pancreatic cancer treatment schedule with gemcitabine, 5-fluorouracil and folinic acid.Target discovery and validation in pancreatic cancer.Role of platinum agents in the management of advanced pancreatic cancer.Pancreatic cancer--is the wall crumbling?Gemcitabine in the treatment of metastatic pancreatic cancer.A comparison of phase II study strategies.A two-cohort phase I study of weekly oxaliplatin and gemcitabine, then oxaliplatin, gemcitabine, and erlotinib during radiotherapy for unresectable pancreatic carcinoma.
P2860
Q33358104-25797216-547D-4651-A57D-C1624A5F0039Q33365031-AF8B53E1-55FC-4D39-B929-A82389F33D87Q33365034-C883271D-D72C-4F6C-B9AA-DBA3E90253B6Q33368773-D5F1569B-C760-4BD2-9059-08711CDE2508Q33371225-1799EEB9-1C61-4B1D-BA3B-0568E1A6A15FQ33372640-40058E25-C657-4E9B-AB33-0D0EDE1922B5Q33374338-E282B368-BFEC-4F36-985D-772CBC0948FEQ33377756-DA879362-64DD-456F-B9F6-178BD984E355Q33378968-934E99AB-0FA4-49CE-BD35-C2C945324F13Q33383091-25775DFC-5944-456C-BD01-19B0D13D8405Q33383758-58F58D65-8320-483C-8BED-59436CCDB474Q33389637-61FF5C2F-0B97-4CCD-809D-5E9A5FA42339Q33394190-20FB40B2-81A5-4262-ACE4-37ADE91065FDQ33400095-99740A41-1D19-45B4-A960-318CA9817FC7Q33428016-5A2AF89C-6B06-4F2F-B041-B868BE056DB8Q33557413-6D2CB0AF-3D53-43D9-87C4-6E89E595B716Q33632330-801DFF7C-026F-4E94-BFCF-7C8C58216659Q34129346-B877975B-9AFE-48D2-8005-2E39F47210C1Q34564463-2C9AA008-4339-47EE-B0BE-76BDC7DA7DD3Q35089138-75B2F05F-1E4A-406F-B4DF-B426D65F6974Q35115259-1A082FF9-1107-49F1-9456-8DBFDE8BDB30Q35161704-17162CF7-813C-455A-B28A-EBCFFB86D4C5Q35202155-BC49F825-DBEE-415E-A73A-5BC60752C6BBQ35576200-4FD49ED6-5C22-4B54-9A26-27E69E4614E0Q35599597-DC5E0985-1608-40A3-8337-415542AF2F39Q35776091-410125A9-D5B8-4C02-88F3-7AE0C0D1B7B2Q36219217-C8C3BBC6-7ED3-45A2-969C-DD51D6D7A6E9Q36351453-4512BDEC-B0F5-4408-8420-A3AB3D158E17Q36384541-0315BC7B-3C9E-4399-A088-E24246BA3507Q36425150-69DFF6A0-D226-44B2-8FCE-A4B22AD48D9CQ36425154-C4489146-DD96-4CDD-8A9B-15629708EB24Q36615060-BDDD6D6A-73CA-40DA-BC41-F4529FCB80C2Q36624100-BB30B9D4-D537-41CC-A326-9BCF285FEED0Q36670901-2DCB055C-8826-442B-AC7A-40842E624980Q36685675-1EFB3CE9-19ED-47F6-978F-E19E0478F141Q36979302-DCAF3F15-00DB-4412-ABEA-C80C5AE65CF1Q37125325-FCC448BB-4E26-4F7B-AFD8-BAEAF4295D7BQ37134412-0BDB3098-D9DF-43A4-8BD9-C971C70C0974Q37375886-E7B0274F-5821-42BF-B725-31BEC55A235CQ37508315-A944C6EB-236D-4F47-9FD8-59D6196AB2CC
P2860
Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study.
description
2002 nî lūn-bûn
@nan
2002 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մարտին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Gemcitabine combined with oxal ...... OR multicenter phase II study.
@ast
Gemcitabine combined with oxal ...... OR multicenter phase II study.
@en
type
label
Gemcitabine combined with oxal ...... OR multicenter phase II study.
@ast
Gemcitabine combined with oxal ...... OR multicenter phase II study.
@en
prefLabel
Gemcitabine combined with oxal ...... OR multicenter phase II study.
@ast
Gemcitabine combined with oxal ...... OR multicenter phase II study.
@en
P2093
P356
P1476
Gemcitabine combined with oxal ...... OR multicenter phase II study.
@en
P2093
A de Gramont
E Cvitkovic
H Bleiberg
P304
P356
10.1200/JCO.20.6.1512
P407
P577
2002-03-01T00:00:00Z